Michael Kharas, Ph.D., associate member at the Molecular Pharmacology Program at Memorial Sloan Kettering Cancer Center, and colleagues have discovered how the protein called Helios impacts a pediatric blood cancer called B-acute lymphoblastic leukemia (B-ALL) and another blood cancer called acute myeloid leukemia (AML). Read more about this important discovery here.
The Leukemia Research Foundation provided funding for Michael Kharas’ research during its 2012 funding cycle. You can find an abstract of his and other LRF-funded research on the Leukemia Research Foundation website here.
For additional information call:
Carl Alston, Director of Communications